tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split

Story Highlights
  • FibroBiologics missed Nasdaq’s $1 bid requirement and faces potential delisting.
  • The company will seek a hearing and shareholder approval for a reverse split to regain compliance, but success remains uncertain.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split

Claim 70% Off TipRanks Premium

An update from FibroBiologics, Inc. ( (FBLG) ) is now available.

On July 1, 2025, FibroBiologics, Inc. was notified by Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive trading days, triggering a 180-day grace period, through December 29, 2025, to regain compliance. After the company failed to meet the requirement by that deadline, Nasdaq staff notified FibroBiologics on December 30, 2025, of its intention to delist the stock unless the company requested a hearing, which FibroBiologics plans to do, temporarily staying any suspension or delisting. The company is monitoring its share price and, as part of its efforts to regain compliance, filed definitive proxy materials on December 29, 2025 seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, though there is no assurance it will secure an extension or that these measures will succeed, leaving its Nasdaq listing status uncertain for investors.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

Spark’s Take on FBLG Stock

According to Spark, TipRanks’ AI Analyst, FBLG is a Neutral.

The score is driven primarily by weak financial performance (no revenue, widening losses, rising cash burn) and a high-risk balance sheet with very thin equity and elevated leverage. Technicals also remain negative with the price below key moving averages and a negative MACD. Valuation provides limited support given ongoing losses and no dividend yield.

To see Spark’s full report on FBLG stock, click here.

More about FibroBiologics, Inc.

FibroBiologics, Inc. is a publicly traded company listed on the Nasdaq Capital Market, with its common stock subject to Nasdaq’s minimum bid price and other continued listing requirements applicable to smaller-cap issuers.

Average Trading Volume: 1,815,869

Technical Sentiment Signal: Sell

Current Market Cap: $14.96M

See more insights into FBLG stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1